Back to top

Image: Bigstock

AVEO Pharmaceuticals, Inc.

Read MoreHide Full Article

AVEO Pharmaceuticals is a biopharmaceutical company that focuses on the development of cancer treatments. AVEO’s performance in the second quarter was impressive with the company reporting a narrower-than-expected loss. AVEO’s lead candidate, tivozanib is being evaluated for several cancer indications including renal cell carcinoma. Meanwhile, securing Novartis as a partner for cachexia candidate, AV-380 is a huge positive for the company. However, AVEO has a limited number of candidates in its pipeline with only one late-stage candidate, tivozanib. Any hiccup in tivozanib’s development would affect the company significantly.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


AVEO Pharmaceuticals, Inc. (AVEO) - free report >>